The generic Micafungin injectable, which is used to treat a range of fungal diseases, has got the final approval from the US health agency, according to Zydus Lifesciences, which announced this on Wednesday.
Micafungin Injection, 50 mg/vial and 100 mg/vial, single-dose vials have received FDA permission for marketing, according to a filing with the stock exchange by Zydus Lifesciences Ltd.
On the BSE, Zydus Lifesciences shares were up roughly 1% to Rs417.25.
Micafungin injection is also used to protect patients receiving stem cell transplants against fungus infections. According to the company, the medication would be produced at the group’s injectable manufacturing facility in Jarod, close to Vadodara, India.
For feedback and suggestions, write to us at editorial@iifl.com
Related Tags
IIFL Customer Care Number
(Gold/NCD/NBFC/Insurance/NPS)
1860-267-3000 / 7039-050-000
IIFL Capital Services Support WhatsApp Number
+91 9892691696
Download The App Now
Follow us on
2026, IIFL Capital Services Ltd. All Rights Reserved
IIFL Capital Services Limited - Stock Broker SEBI Regn. No: INZ000164132 (Member ID - NSE: 10975 BSE: 179 MCX: 55995 NCDEX: 01249), DP SEBI Reg. No. IN-DP-185-2016, PMS SEBI Regn. No: INP000002213, IA SEBI Regn. No: INA000000623, Merchant Banker SEBI Regn. No. INM000010940, RA SEBI Regn. No: INH000000248, BSE Enlistment Number (RA): 5016, AMFI-Registered Mutual Fund Distributor & SIF Distributor
ARN NO : 47791 (Date of initial registration – 17/02/2007; Current validity of ARN – 08/02/2027), PFRDA Reg. No. PoP 20092018, IRDAI Corporate Agent (Composite) : CA1099
This Certificate Demonstrates That IIFL As An Organization Has Defined And Put In Place Best-Practice Information Security Processes.
